Bacterin International Holdings Inc (NYSEMKT:BONE)’s shares increased 14.29% and closed at $0.96 in yesterday’s session. The company on Mar. 20 announces that results utilizing OsteoSponge® bone graft for foot and ankle arthrodeses procedures has been published in the peer-reviewed journal Orthopedics. Bacterin International Holdings Inc (NYSEMKT:BONE) shares after opening at $1.02 moved to $1.09 on last trade day and at the end of the day closed at $0.980. Company price to sales ratio in past twelve months was calculated as 1.54 and price to cash ratio as 14.88. Bacterin International Holdings Inc (NYSEMKT:BONE) showed a positive weekly performance of 32.43%.
AVEO Pharmaceuticals Inc. (Nasdaq:AVEO) jumped 15% to $1.88 after regaining worldwide rights from Biogen Idec Inc. (Nasdaq:BIIB). The rights are in regard to AV-203, an antibody that reportedly has broad therapeutic potential for the treatment of cancer and other diseases. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares advanced 7.19% in last trading session and ended the day on $1.79. AVEO return on equity ratio is recorded as -98.30% and its return on assets is -56.70%. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) yearly performance is -76.87%.
Dyax Corp. (NASDAQ:DYAX) entered into an Underwriting Agreement with Jefferies LLC, as representative of the several underwriters (the “Underwriting Agreement”), pursuant to which the Company agreed to offer and sell 8,000,000 shares of its common stock in an underwritten public offering at a public offering price of $9.25 per share. Pursuant to the terms of the Underwriting Agreement, the Company granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares. Dyax Corp. (NASDAQ:DYAX) shares moved down -5.13% in last trading session and was closed at $8.88 while trading in range of $8.81 – $9.38 – Dyax Corp. (NASDAQ:DYAX) year to date (YTD) performance is 17.77%.
Merrimack Pharmaceuticals (NASDAQ:MACK) announced a $200 million mixed securities shelf. The company may sell Debt Securities, Common Stock, Preferred Stock, or others. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) weekly performance is -5.67%. On last trading day company shares ended up $5.32. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) distance from 50-day simple moving average (SMA50) is -2.30%. Analysts mean target price for the company is $10.08.